市場調査レポート: ブドウ膜黒色腫：市場機会の評価、疫学研究、市場力学、パイプライン分析：2020年上半期

	市場調査レポートブドウ膜黒色腫：市場機会の評価、疫学研究、市場力学、パイプライン分析：2020年上半期 Uveal Melanoma - Opportunity Assessments, Epidemiological Studies, Market Dynamics and Pipeline Analytics, H1 2020
発行	GervanoRA Data Services LLP			商品コード	944097
出版日	2020年06月23日	ページ情報	英文 157 Pages
価格	PDF (General License) USD 2,500 換算 270,775円 (税抜) レポートPDFを同一企業の全世界の方にご使用頂けるライセンスです。ご利用人数に制限はありません。100％子会社は同一企業とみなされます。PDF内のテキスト等のコピー＆ペースト可能です。PDの印刷は何回でも可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。本日の銀行送金レート: 1USD=108.31円で換算しております。

概要

比較する

当レポートは、2020年上半期のブドウ膜黒色腫の関連市場を調査したもので、疾病と市場の概要、市場の力学、パイプラインの分析、パイプライン上にある医薬品の分析と開発スケジュール、医薬品承認時期の予測、競合企業の比較評価による市場機会の見積もり、現在と将来の競合情勢などの情報を提供しています。

LIST OF TABLES

TABLE 01: UVEAL MELANOMA REPORT HIGHLIGHTS IN NUMERICALS
TABLE 02: UVEAL MELANOMA AFFECTED POPULATION GLOBALLY
TABLE 03: COLLABORATION DEALS IN UVEAL MELANOMA THERAPEUTIC AREA
TABLE 04: LICENSING DEALS IN UVEAL MELANOMA THERAPEUTIC AREA
TABLE 05: FINANCING DEALS IN UVEAL MELANOMA THERAPEUTIC AREA
TABLE 06: IMMUNOCORE GRANTED PATENTS ANALYTICS
TABLE 07: IMMUNOCORE PATENT APPLICATIONS FILED
TABLE 08: ISSUED PATENTS ANALYTICS OF BIOMED VALLEY DISCOVERIES
TABLE 09: BIOMED VALLEY DISCOVERIES PATENT APPLICATIONS FILED
TABLE 10: GLOBAL PATENTS OF BIOMED VALLEY DISCOVERIES
TABLE 11: GRANTED PATENT ANALYTICS OF AURA BIOSCIENCES
TABLE 12: AURA BIOSCIENCES PATENT APPLICATIONS FILED
TABLE 13: GRANTED PATENTS ANALYTICS OF PROVECTUS BIOPHARMACEUTICALS
TABLE 14: UVEAL MELANOMA PIPELINE DRUGS BY STAGE OF DEVELOPMENT
TABLE 15: UVEAL MELANOMA PHASE III PIPELINE MOLECULES
TABLE 16: UVEAL MELANOMA PHASE II PIPELINE MOLECULES
TABLE 17: UVEAL MELANOMA PHASE I/II PIPELINE MOLECULES
TABLE 18: UVEAL MELANOMA PHASE I PIPELINE MOLECULES
TABLE 19: PRECLINICAL STAGE DRUG CANDIDATES FOR UVEAL MELANOMA
TABLE 20: LIST OF PIPELINE MOLECULES OF PARENTERAL ROUTE OF ADMINISTRATION
TABLE 21: LIST OF PIPELINE MOLECULES OF ORAL ROUTE OF ADMINISTRATION
TABLE 22: PIPELINE DRUGS AFFECTING ON T-CELL RECEPTORS
TABLE 23: LIST OF PIPELINE DRUGS OF KINASE INHIBITORS
TABLE 24: LIST OF PIPELINE MOLECULES WITH THEIR MECHANISM OF ACTIONS
TABLE 25: LIST OF PIPELINE DRUGS WITH THEIR MOLECULE TYPE
TABLE 26: LIST OF PIPELINE MOLECULES WITH THEIR MOLECULAR TARGETS
TABLE 27: UVEAL MELANOMA PIPELINE DRUGS ANALYTICS BY COMPANY TYPE
TABLE 28: REGION WISE STATISTICS, COMPANY COUNT WITH COUNT OF UVEAL MELANOMA PIPELINE CANDIDATES
TABLE 29: DEVELOPMENT MILESTONES OF MELPHALAN HYDROCHLORIDE WITH HDS
TABLE 30: DEVELOPMENT MILESTONES OF SELUMETINIB
TABLE 31: DEVELOPMENT MILESTONES OF TEBENTAFUSP (IMCGP100)
TABLE 32: DEVELOPMENT MILESTONES OF ULIXERTINIB
TABLE 33: GERVANORA ESTIMATED APPROVAL TIMELINES V/S ACTUAL APPROVAL DATE
TABLE 34: UVEAL MELANOMA PIPELINE DRUGS (PHASE III AND PHASE II) ESTIMATED APPROVAL TIMELINES
TABLE 35: US PATENTS PORTFOLIO OF PROVECTUS BIOPHARMACEUTICALS
TABLE 36: RANKING OF TOP EMERGING COMPANIES BASED ON REGULATORY ALLOWANCES
TABLE 37: PIPELINE ASSETS OF IMMUNOCORE WITH RESPECT TO ONCOLOGY TREATMENTS
TABLE 38: PIPELINE ASSETS OF IMMUNOCORE WITH RESPECT TO INFECTIOUS DISEASE TREATMENTS
TABLE 39: PATENTS GRANTED TO IMMUNOCORE
TABLE 40: PATENT APPLICATIONS FILED BY IMMUNOCORE
TABLE 41: RESEARCH AND DEVELOPMENT ACTIVITIES AND RECENT DEVELOPMENTS OFIMMUNOCORE
TABLE 42: PRESENTATIONS AND EVENTS OF IMMUNOCORE
TABLE 43: PIPELINE ASSETS OF DELCATH SYSTEMS
TABLE 44: RESEARCH AND DEVELOPMENT ACTIVITIES AND RECENT DEVELOPMENTS OF DELCATH SYSTEMS
TABLE 45: PRESENTATIONS AND EVENTS OF DELCATH SYSTEMS
TABLE 46: PIPELINE ASSETS OF IDEAYA BIOSCIENCES WITH RESPECT TO KINASE
TABLE 47: PIPELINE ASSETS OF IDEAYA BIOSCIENCES WITH RESPECT TO SYNTHETIC LETHALITY
TABLE 48: RESEARCH AND DEVELOPMENT ACTIVITIES OF IDEAYA BIOSCIENCES
TABLE 49: RECENT DEVELOPMENTS OF IDEAYA BIOSCIENCES
TABLE 50: PRESENTATIONS AND EVENTS OF IDEAYA BIOSCIENCES
TABLE 51: PIPELINE ASSETS OF BIOMED VALLEY DISCOVERIES
TABLE 52: PATENTS ISSUED TO BIOMED VALLEY DISCOVERIES IN THE U.S
TABLE 53: PATENT APPLICATIONS FILED BY BIOMED VALLEY DISCOVERIES IN THE U.S
TABLE 54: PATENTS AND PATENT APPLICATIONS FILED BY BIOMED VALLEY DISCOVERIES OTHER THAN THE U.S
TABLE 55: RESEARCH AND DEVELOPMENT ACTIVITIES AND RECENT DEVELOPMENTS OF BIOMED VALLEY DISCOVERIES
TABLE 56: PRESENTATIONS AND EVENTS OF BIOMED VALLEY DISCOVERIES
TABLE 57: PUBLICATIONS OF BIOMED VALLEY DISCOVERIES
TABLE 58: PATENTS ISSUED TO AURA BIOSCIENCES
TABLE 59: PATENT APPLICATIONS FILED BY AURA BIOSCIENCES
TABLE 60: RESEARCH AND DEVELOPMENT ACTIVITIES AND RECENT DEVELOPMENTS OFAURA BIOSCIENCES
TABLE 61: PRESENTATIONS AND EVENTS OF AURA BIOSCIENCES
TABLE 62: PUBLICATIONS OFAURA BIOSCIENCES
TABLE 63: PIPELINE ASSETS OF REPLIMUNE
TABLE 64: RESEARCH AND DEVELOPMENT ACTIVITES OF REPLIMUNE
TABLE 65: PIPELINE ASSETS OF FARON PHARMACEUTICALS
TABLE 66: RESEARCH AND DEVELOPMENT ACTIVITIES OF FARON PHARMACEUTICALS
TABLE 67: RECENT DEVELOPMENTS OF FARON PHARMACEUTICALS
TABLE 68: PRESENTATIONS AND EVENTS OF FARON PHARMACEUTICALS
TABLE 69: PIPELINE ASSETS OF PROVECTUS BIOPHARMACEUTICALS
TABLE 70: US PATENTS PORTFOLIO OF PROVECTUS BIOPHARMACEUTICALS
TABLE 71: RESEARCH AND DEVELOPMENT AND PRESENTATIONS OF PROVECTUS BIOPHARMACEUTICALS
TABLE 72: RECENT DEVELOPMENTS OF PROVECTUS BIOPHARMACEUTICALS
TABLE 73: PIPELINE ASSETS OF AEGLEA BIOTHERAPEUTICS
TABLE 74: RESEARCH AND DEVELOPMENT ACTIVITIES OF AEGLEA BIOTHERAPEUTICS
TABLE 75: RECENT DEVELOPMENTS OF AEGLEA BIOTHERAPEUTICS
TABLE 76: PRESENTATIONS AND EVENTS OF AEGLEA BIOTHERAPEUTICS
TABLE 77: PIPELINE ASSETS OF INVENTIVA PHARMA
TABLE 78: RESEARCH AND DEVELOPMENT ACTIVITIES AND RECENT DEVELOPMENTS OF INVENTIVA PHARMA
TABLE 79: PRESENTATION AND EVENTS OF INVENTIVA PHARMA
TABLE 80: PIPELINE ASSETS OF AEGLEA BIOTHERAPEUTICS
TABLE 81: RESEARCH AND DEVELOPMENT ACTIVITIES AND RECENT DEVELOPMENTS OF BELLICUM PHARMACEUTICALS
TABLE 82: PRESENTATIONS AND EVENTS OF BELLICUM PHARMACEUTICALS
TABLE 83: PATENTS ISSUED TO EXELIXIS IN THE U.S
TABLE 84: PATENTS ISSUED TO EXELIXIS IN EUROPE
TABLE 85: RESEARCH AND DEVELOPMENT ACTIVITIES OF EXELIXIS
TABLE 86: RECENT DEVELOPMENTS OF EXELIXIS
TABLE 87: PRESENTATIONS AND EVENTS OF EXELIXIS
TABLE 88: PIPELINE ASSETS OF IOVANCE BIOTHERAPEUTICS
TABLE 89: RESEARCH AND DEVELOPMENT ACTIVITES OF IOVANCE BIOTHERAPEUTICS
TABLE 90: RECENT DEVELOPMENTS OF IOVANCE BIOTHERAPEUTICS
TABLE 91: PRESENTATION AND EVENTS OF IOVANCE BIOTHERAPEUTICS

LIST OF FIGURES

FIGURE 01: KEY EVENTS IN THE UVEAL MELANOMA COMPETITIVE SPACE
FIGURE 02: UVEAL MELANOMA DEAL ANALYTICS BY DEAL TYPE
FIGURE 03: UVEAL MELANOMA DEAL ANALYTICS BY DEAL FREQUENCY TILL MAY 2020
FIGURE 04: PIPELINE MOLECULES - CLINICAL VS PRECLINICAL & EARLY R&D
FIGURE 05: TOTAL PIPELINE MOLECULES VS STAGE OF DEVELOPMENT
FIGURE 06: UM DRUGS PIPELINE ANALYTICS BY ROA
FIGURE 07: UM DRUGS PIPELINE ANALYTICS BY PARENTERAL ROA
FIGURE 08: PARENTERAL DRUGS PIPELINE ANALYTICS BY HSD
FIGURE 09: ORAL DRUGS PIPELINE ANALYTICS BY STAGE OF DEVELOPMENT
FIGURE 10: TOTAL PIPELINE MOLECULES V/S DRUG CLASSES
FIGURE 11: PIPELINE DRUG CLASS ANALYTICS BY STAGE OF DEVELOPMENT
FIGURE 12: UVEAL MELANOMA PIPELINE DRUGS BIOLOGICALS VS SMALL MOLECULES
FIGURE 13: UVEAL MELANOMA PIPELINE DRUGS ANALYTICS BY MOLECULE TYPE VS STAGE OF DEVELOPMENT
FIGURE 14: UVEAL MELANOMA COMPANIES (NUMBER, PERCENT SHARE)
FIGURE 15: GEOGRAPHICAL CATEGORIZATION OF COMPANIES WORKING ON UVEAL MELANOMA
FIGURE 16: COUNT OF COMPANIES FOCUSED ON CANCER BASED THERAPIES
FIGURE 17: RESEARCH AND DEVELOPMENT EXPENSES OF TOP 5 COMPANIES IN $M
FIGURE 18: EXTERNAL FUNDING RECEIVED BY THE COMPANIES IN $M
FIGURE 19: PIPELINE PORTFOLIO WITH (NUMBER OF MOLECULES)
FIGURE 20: EXPECTED MARKET ENTRY WITH RESPECT TO DRUG CANDIDATES TREATING UVEAL MELANOMA
FIGURE 21: TIME LINE OF PATENT EXPIRIES WITH RESPECT TO UVEAL MELANOMA TREATMENTS
FIGURE 22: RANKING TOP 5 EMERGING COMPANIES BASED ON THEIR PARTNERING ACTIVITIES
FIGURE 23: R&D EXPENSES FOR THE FINANCIAL YEARS OF 2018 AND 2019 BY DELCATH SYSTEMS IN $K
FIGURE 24: R&D EXPENSES FOR THE FINANCIAL YEARS OF 2017, 2018 AND 2019 BY IDEAYA BIOSCIENCES IN $K
FIGURE 25: R&D EXPENSES FOR THE FINANCIAL YEARS OF 2017, 2018 AND 2019 BY AEGLEA BIOTHERAPEUTICS IN $K
FIGURE 26: R&D EXPENSES FOR THE FINANCIAL YEARS OF 2018 AND 2019 BY BELLICUM PHARMACEUTICALS IN $K
FIGURE 27: R&D EXPENSES FOR THE FINANCIAL YEARS OF 2018 AND 2019 BY EXELIXIS IN $K
FIGURE 28: R&D EXPENSES FOR THE FINANCIAL YEARS OF 2018 AND 2019 BY IOVANCE BIOTHERAPEUTICS IN $K

Product Code: GERPH786

GervanoRA's pipeline analysis and opportunity assessment report "Uveal Melanoma - Opportunity Assessments, Epidemiological Studies, Market Dynamics and Pipeline Analytics, H1 2020" analysed and assessed Uveal Melanoma pipeline molecules for the opportunities in the competitive space by covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Uveal Melanoma drugs industry.

The report has been divided into segments like Disease Overview, Market Overview, Pipeline Analytics to provide in depth insights about the market dynamics and ongoing R&D in the Uveal Melanoma disease area. The report provides detailed insights about all the pipeline molecules in different stages of development and all the companies which are actively involved in Uveal Melanoma drugs industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Analytics by Stage of Development, Pipeline Analytics by Route of Administration, Pipeline Analytics by Geography, Pipeline Analytics by Mechanism of Action, Pipeline Analytics by Drug Class, Pipeline Analytics by Molecule Type, Pipeline Analytics by Target and Pipeline Analytics by Company Type. The report has also highlighted the universities and institutes working on the development of new innovative therapeutics for the treatment of Uveal Melanoma.

Our comprehensive analysis on the Uveal Melanoma drug pipeline identified 53 drug candidates undergoing different stages of development- from Pre-clinical stage to Phase 3 stage. Among these, a total of 44 drug candidates are in clinical stages of development and 09 molecules are in non-clinical stage of development. The drug pipeline consists of four (4) pipeline molecules in late clinical stage of development (Phase III), and a total of 17 pipeline molecules in early clinical stage of development (Phase I).

The report has covered a total of 32 companies worldwide, involved in the development of new therapeutics. Growth opportunities in the report have been provided by performing a competitive and comparative analysis on the top 10 Emerging companies in the domain and hence deriving the key leader.

Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:

Unmet needs and Opportunities

Market Dynamics with Coverage of Deals (Licensing, Partnering, Collaborations, Financing etc.)

Patent Analytics of Pipeline Molecules

Pipeline Analysis of all Drug Molecules and Estimated Pipeline Drug Approval Time lines of Late Clinical Stage (Phase 2 and Phase 3) Pipeline Drug Candidates

Clinical Stage Drug Candidates' Descriptions along with Development Milestones

Opportunity Assessments through Competitive Benchmarking

Evaluate Current and Future Competitive Landscape through Company Profiles

Emerging Company Profiles with Opportunity Assessments

Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.

CHAPTER 01: INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. METHODOLOGY
1.3. ABOUT US: GERVANORA DATA SERVICES

CHAPTER 02: EXECUTIVE SUMMARY

2.1. REPORT SUMMARY
2.2. KEY EVENTS IN THE UVEAL MELANOMA COMPETITIVE SPACE
2.3. REPORT MAJOR FINDINGS
- 2.3.1. DRIVERS
- 2.3.2. RESTRAINTS
- 2.3.3. OPPORTUNITIES

CHAPTER 03: DISEASE OVERVIEW

3.1. DISEASE DEFINITION AND SYMPTOMS
3.2. DISEASE CAUSE AND PATHOPHYSIOLOGY
3.3. DISEASE DIAGNOSIS
3.4. TREATMENT ALGORITHM AND GUIDELINES
3.5. EPIDEMIOLOGY STUDIES
- 3.5.1. GLOBAL AND HISTORICAL TRENDS
3.6. EPIDEMIOLOGY FORECAST
- 3.6.1. FORECAST METHODOLOGY AND ASSUMPTIONS
- 3.6.2. PROBABILISTIC EPIDEMIOLOGY FORECAST

CHAPTER 04: MARKET DYNAMICS OF UVEAL MELANOMA THERAPIES

4.1. DEALS (MERGERS/ ACQUISITIONS/ COLLABORATIONS)
- 4.1.1 DEALS ANALYTICS BY DEAL TYPE
  - 4.1.1.1. COLLABORATION DEALS
  - 4.1.1.2. LICENSING DEALS
  - 4.1.1.3. FINANCING DEALS
- 4.1.2 DEALS ANALYTICS BY ANNUAL FREQUENCY
- 4.1.3 DEALS ANALYTICS BY ACTIVE PLAYER
4.2. PATENT ANALYSIS (EXPIRIES AND GENERICIZATION)
- 4.2.1. PATENT ANALYTICS OF PIPELINE DRUGS

CHAPTER 05: PIPELINE DRUGS ANALYTICS OF UVEAL MELANOMA

5.1. PIPELINE DRUGS ANALYTICS BY STAGE OF DEVELOPMENT
- 5.1.1. PHASE III PIPELINE DRUGS
- 5.1.2. PHASE II PIPELINE DRUGS
- 5.1.3. PHASE I/II PIPELINE DRUGS
- 5.1.4. PHASE I PIPELINE DRUGS
- 5.1.5. PRE-CLINICAL PIPELINE DRUGS
5.2. PIPELINE DRUGS ANALYTICS BY GEOGRAPHY
5.3. PIPELINE DRUGS ANALYTICS BY ROUTE OF ADMINISTRATION
5.4. PIPELINE DRUGS ANALYTICS BY DRUG CLASS
5.5. PIPELINE DRUGS ANALYTICS BY MECHANISM OF ACTION
5.6. PIPELINE DRUGS ANALYTICS BY MOLECULE TYPE
5.7. PIPELINE DRUGS ANALYTICS BY TARGET RECEPTORS
5.8. PIPELINE DRUGS ANALYTICS BY COMPANY TYPE

CHAPTER 06: PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES

6.1. PHASE III PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES
6.2. PHASE II PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES
6.3. PHASE I/II PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES
6.4. PHASE I PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES

CHAPTER 07: ESTIMATED APPROVAL TIMELINES OF UVEAL MELANOMA PIPELINE DRUGS

7.1. METHODOLOGY
7.2. ESTIMATED APPROVAL TIMELINES US & EX-US

CHAPTER 8: OPPORTUNITY ASSESSMENTS THROUGH COMPETITIVE BENCH-MARKING

8.1. EXTERNAL DEPENDENCIES
- 8.1.1. BUSINESS R&D - INTERNAL INVESTMENT AND EXTERNAL FUNDING
8.2. PIPELINE PORTFOLIO
8.3. EXPECTED MARKET ENTRIES
8.4. PATENTS AND EXCLUSIVITY
8.5. MARKET DYNAMICS AND PARTNERING
8.6. ACHIEVEMENTS OF SPECIAL REGULATORY ALLOWANCES
8.7. COMPANY DEVELOPMENTS

CHAPTER 9: CURRENT AND FUTURE COMPETITIVE LANDSCAPE

9.1. EMERGING COMPANIES
- 9.1.1 EMERGING COMPANY PROFILES

044-952-0102

(土日・祝日を除く)

よくあるご質問

ブドウ膜黒色腫：市場機会の評価、疫学研究、市場力学、パイプライン分析：2020年上半期

Uveal Melanoma - Opportunity Assessments, Epidemiological Studies, Market Dynamics and Pipeline Analytics, H1 2020

目次

第1章イントロダクション

第2章エグゼクティブサマリー

第3章疾患の概要

第4章市場の力学

第5章パイプライン上にある医薬品の分析

第6章パイプライン薬の説明と開発マイルストーン

第7章パイプライン上にある医薬品の予想される承認時期

第8章競合企業各社の機会の評価

第9章現在と将来の競合情勢

LIST OF TABLES

LIST OF FIGURES

TABLE OF CONTENTS

CHAPTER 01: INTRODUCTION

CHAPTER 02: EXECUTIVE SUMMARY

CHAPTER 03: DISEASE OVERVIEW

CHAPTER 04: MARKET DYNAMICS OF UVEAL MELANOMA THERAPIES

CHAPTER 05: PIPELINE DRUGS ANALYTICS OF UVEAL MELANOMA

CHAPTER 06: PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES

CHAPTER 07: ESTIMATED APPROVAL TIMELINES OF UVEAL MELANOMA PIPELINE DRUGS

CHAPTER 8: OPPORTUNITY ASSESSMENTS THROUGH COMPETITIVE BENCH-MARKING

CHAPTER 9: CURRENT AND FUTURE COMPETITIVE LANDSCAPE

ブドウ膜黒色腫：市場機会の評価、疫学研究、市場力学、パイプライン分析：2020年上半期 Uveal Melanoma - Opportunity Assessments, Epidemiological Studies, Market Dynamics and Pipeline Analytics, H1 2020
出版日: 2020年06月23日	ページ情報: 英文 157 Pages

ブドウ膜黒色腫：市場機会の評価、疫学研究、 市場力学、パイプライン分析：2020年上半期

Uveal Melanoma - Opportunity Assessments, Epidemiological Studies, Market Dynamics and Pipeline Analytics, H1 2020

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 疾患の概要

第4章 市場の力学

第5章 パイプライン上にある医薬品の分析

第6章 パイプライン薬の説明と開発マイルストーン

第7章 パイプライン上にある医薬品の予想される承認時期

第8章 競合企業各社の機会の評価

第9章 現在と将来の競合情勢

LIST OF TABLES

LIST OF FIGURES

TABLE OF CONTENTS

CHAPTER 01: INTRODUCTION

CHAPTER 02: EXECUTIVE SUMMARY

CHAPTER 03: DISEASE OVERVIEW

CHAPTER 04: MARKET DYNAMICS OF UVEAL MELANOMA THERAPIES

CHAPTER 05: PIPELINE DRUGS ANALYTICS OF UVEAL MELANOMA

CHAPTER 06: PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES

CHAPTER 07: ESTIMATED APPROVAL TIMELINES OF UVEAL MELANOMA PIPELINE DRUGS

CHAPTER 8: OPPORTUNITY ASSESSMENTS THROUGH COMPETITIVE BENCH-MARKING

CHAPTER 9: CURRENT AND FUTURE COMPETITIVE LANDSCAPE

ブドウ膜黒色腫：市場機会の評価、疫学研究、市場力学、パイプライン分析：2020年上半期

第1章イントロダクション

第2章エグゼクティブサマリー

第3章疾患の概要

第4章市場の力学

第5章パイプライン上にある医薬品の分析

第6章パイプライン薬の説明と開発マイルストーン

第7章パイプライン上にある医薬品の予想される承認時期

第8章競合企業各社の機会の評価

第9章現在と将来の競合情勢